Plot graphs for GLP-1 Receptor Agonists Semaglutide (Ozempic/Wegovy/Rybelsus), Tirzepatide (Mounjaro) & Retatrutide based on dose & half-life.

Plot Your Dose

Use our Plotter to visualize the concentration of your GLP-1 Receptor Agonist over time. This tool works as a dose calculator to help you estimate the levels of the drug in your system at any time for varying doses and timing.

NOTE: Everyone is different, and physiology can differ vastly between different people. We aim to make our calculator as accurate as possible based on publicly available data. However, the half-lives of these compounds are estimates and will differ between individuals, so caution should be advised. Use at your own risk.



  • Semaglutide is sold under the brand names Ozempic, Wegovy and Rybelsus.
  • The Semaglutide half-life is estimated to be around seven days (source 1, source 2) for both injectable and oral forms.
  • The absolute bioavailability of Semaglutide injections is 89% (source).
  • The estimated bioavailability of Semaglutide following oral administration is approximately 1% (source).
  • The recommended dosage for Semaglutide is as follows:
    • 0.25 mg once weekly for the first 4 weeks
    • 0.5 mg once weekly for at least 4 weeks
    • 1 mg once weekly for at least 4 weeks, but only if additional glycemic control is needed
    • 2mg once weekly if additional control is needed
  • Semaglutide injections should be dosed subcutaneously.


  • Tirzepatide is sold under the brand name Mounjaro.
  • The Tirzepatide half-life is estimated to be around five days (source).
  • The mean absolute bioavailability of Tirzepatide following subcutaneous administration is 80% (source).
  • The recommended dosage for Tirzepatide is as follows:
    • 2.5 mg once weekly for the first 4 weeks
    • 5 mg once weekly for at least 4 weeks
    • If additional glycemic control is needed, then the dosage can be increased by 2.5 mg after at least 4 weeks on the current dose
    • The maximum dose is 15mg once weekly
  • Tirzepatide should be dosed subcutaneously.
  1. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
  2. Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
  3. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying